Currently, there are 57.89M common shares owned by the public and among those 55.44M shares have been available to trade.
The company’s stock has a 5-day price change of 2.12% and -15.99% over the past three months. AGIO shares are trading -9.31% year to date (YTD), with the 12-month market performance down to -12.04% lower. It has a 12-month low price of $23.42 and touched a high of $62.58 over the same period. AGIO has an average intraday trading volume of 641.36K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.02%, 2.87%, and -23.57% respectively.
Institutional ownership of Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares accounts for 105.63% of the company’s 57.89M shares outstanding.
It has a market capitalization of $1.73B and a beta (3y monthly) value of 0.70. The stock’s trailing 12-month PE ratio is 2.64, while the earnings-per-share (ttm) stands at $11.29. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.26% over the week and 2.73% over the month.
Analysts forecast that Agios Pharmaceuticals Inc (AGIO) will achieve an EPS of -1.78 for the current quarter, -1.91 for the next quarter and -6.29 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -1.92 while analysts give the company a high EPS estimate of -1.92. Comparatively, EPS for the current quarter was -1.69 a year ago. Earnings per share for the fiscal year are expected to decrease by -162.17%, and 8.34% over the next financial year.
Looking at the support for the AGIO, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on February 24, 2025, with the firm’s price target at $58. Raymond James was of a view on October 10, 2024 that the stock is Outperform, while Leerink Partners gave the stock Market Perform rating on September 27, 2024, issuing a price target of $60- $56. Cantor Fitzgerald on their part issued Overweight rating on February 08, 2024.
